Drug Profile
Trafermin - Nobelpharma
Alternative Names: NPC 18; RetympaLatest Information Update: 20 Jul 2023
Price :
$50
*
At a glance
- Originator Nobelpharma
- Developer Harvard University; Kaken Pharmaceutical; Massachusetts Eye and Ear; Nobelpharma
- Class Fibroblast growth factors; Peptide fragments; Vascular disorder therapies
- Mechanism of Action Angiogenesis inducing agents; Fibroblast growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Ear disorders
- Phase III Hearing disorders
Most Recent Events
- 20 Jul 2023 Phase-III clinical trials in Hearing disorders in Japan (unspecified route) before July 2023 (Nobelpharma pipeline, July 2023)
- 20 Jul 2023 Nobel pharma expects approval for Hearing-disorders in March 2026 (Nobelpharma pipeline, July 2023)
- 27 Aug 2019 Nobel pharma expects approval for Ear disorders in Japan (Otic) in September 2019 (Nobelpharma pipeline, August 2019)